This HTML5 document contains 137 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
n28http://linked.opendata.cz/resource/drugbank/drug/DB00649/identifier/kegg-drug/
dctermshttp://purl.org/dc/terms/
n25http://linked.opendata.cz/resource/drugbank/drug/DB00649/identifier/drugbank/
n19http://linked.opendata.cz/resource/AHFS/
n9http://linked.opendata.cz/resource/drugbank/company/
n33http://linked.opendata.cz/resource/mesh/concept/
foafhttp://xmlns.com/foaf/0.1/
n29http://linked.opendata.cz/resource/drugbank/drug/DB00649/identifier/national-drug-code-directory/
n17http://linked.opendata.cz/resource/drugbank/dosage/
n18http://linked.opendata.cz/resource/drugbank/mixture/
n31http://bio2rdf.org/drugbank:
n24http://linked.opendata.cz/resource/drugbank/drug/DB00649/identifier/chemspider/
admshttp://www.w3.org/ns/adms#
n14http://www.rxlist.com/cgi/generic/
n21http://linked.opendata.cz/resource/drugbank/patent/
n12http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
n16http://linked.opendata.cz/resource/drugbank/drug/DB00649/identifier/wikipedia/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n13http://linked.opendata.cz/resource/drugbank/medicinal-product/
owlhttp://www.w3.org/2002/07/owl#
n26http://linked.opendata.cz/resource/drugbank/drug/DB00649/identifier/pharmgkb/
n32http://linked.opendata.cz/ontology/mesh/
n6http://linked.opendata.cz/ontology/drugbank/
n30http://www.drugs.com/cdi/
n23http://linked.opendata.cz/resource/drugbank/drug/DB00649/identifier/kegg-compound/
n10http://linked.opendata.cz/resource/drugbank/property/
n5http://www.pdrhealth.com/drug_info/rxdrugprofiles/drugs/
n20http://linked.opendata.cz/resource/drugbank/drug/DB00649/identifier/bindingdb/
xsdhhttp://www.w3.org/2001/XMLSchema#
n27http://linked.opendata.cz/resource/drugbank/drug/DB00649/identifier/pubchem-compound/
n8http://linked.opendata.cz/resource/atc/
n22http://linked.opendata.cz/resource/drugbank/drug/DB00649/identifier/pubchem-substance/
n7http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB00649
rdf:type
n6:Drug
n6:description
A dideoxynucleoside analog that inhibits reverse transcriptase and has in vitro activity against HIV. [PubChem]
n6:dosage
n17:271B6168-363D-11E5-9242-09173F13E4C5 n17:271B6169-363D-11E5-9242-09173F13E4C5 n17:271B6164-363D-11E5-9242-09173F13E4C5 n17:271B6165-363D-11E5-9242-09173F13E4C5 n17:271B6166-363D-11E5-9242-09173F13E4C5 n17:271B6167-363D-11E5-9242-09173F13E4C5 n17:271B6160-363D-11E5-9242-09173F13E4C5 n17:271B6161-363D-11E5-9242-09173F13E4C5 n17:271B6162-363D-11E5-9242-09173F13E4C5 n17:271B6163-363D-11E5-9242-09173F13E4C5 n17:271B615F-363D-11E5-9242-09173F13E4C5
n6:group
investigational approved
n6:halfLife
0.8-1.5 hours (in adults)
n6:indication
For the treatment of human immunovirus (HIV) infections.
n6:manufacturer
n9:271B6150-363D-11E5-9242-09173F13E4C5 n9:271B6151-363D-11E5-9242-09173F13E4C5 n9:271B614F-363D-11E5-9242-09173F13E4C5 n9:271B6154-363D-11E5-9242-09173F13E4C5 n9:271B6155-363D-11E5-9242-09173F13E4C5 n9:271B6152-363D-11E5-9242-09173F13E4C5 n9:271B6153-363D-11E5-9242-09173F13E4C5
owl:sameAs
n12:DB00649 n31:DB00649
dcterms:title
Stavudine
adms:identifier
n16:Stavudine n20:50013111 n22:46506943 n23:C07312 n24:17270 n25:DB00649 n26:PA451494 n27:18283 n28:D00445 n29:0179-0028-70
n6:mechanismOfAction
Stavudine inhibits the activity of HIV-1 reverse transcriptase (RT) both by competing with the natural substrate dGTP and by its incorporation into viral DNA.
n6:packager
n9:271B6140-363D-11E5-9242-09173F13E4C5 n9:271B6141-363D-11E5-9242-09173F13E4C5 n9:271B613E-363D-11E5-9242-09173F13E4C5 n9:271B613F-363D-11E5-9242-09173F13E4C5 n9:271B613D-363D-11E5-9242-09173F13E4C5 n9:271B613C-363D-11E5-9242-09173F13E4C5 n9:271B6148-363D-11E5-9242-09173F13E4C5 n9:271B6149-363D-11E5-9242-09173F13E4C5 n9:271B6146-363D-11E5-9242-09173F13E4C5 n9:271B6147-363D-11E5-9242-09173F13E4C5 n9:271B6144-363D-11E5-9242-09173F13E4C5 n9:271B6145-363D-11E5-9242-09173F13E4C5 n9:271B6142-363D-11E5-9242-09173F13E4C5 n9:271B6143-363D-11E5-9242-09173F13E4C5 n9:271B614E-363D-11E5-9242-09173F13E4C5 n9:271B614C-363D-11E5-9242-09173F13E4C5 n9:271B614D-363D-11E5-9242-09173F13E4C5 n9:271B614A-363D-11E5-9242-09173F13E4C5 n9:271B614B-363D-11E5-9242-09173F13E4C5
n6:patent
n21:7135465
n6:synonym
Stavudin Estavudina 1-(2,3-Dideoxy-beta-D-glycero-pent-2-enofuranosyl)thymine 2',3'-Didehydro-3'-deoxythimidine STV Sanilvudine Stavudinum Stavudine 3'-Deoxy-2'-thymidinene d4T
n6:toxicity
Side effects include peripheral neuropathy tingling, burning, numbness, or pain in the hands or feet), fatal lactic acidosis has been reported in patients treated with stavudine (ZERIT) in combination with other antiretroviral agents, severe liver enlargement, inflammation (pain and swelling) of the liver, and liver failure.
n6:volumeOfDistribution
* 46 ± 21 L
n7:hasAHFSCode
n19:08-18-08-20
n6:mixture
n18:271B6139-363D-11E5-9242-09173F13E4C5 n18:271B613A-363D-11E5-9242-09173F13E4C5 n18:271B6137-363D-11E5-9242-09173F13E4C5 n18:271B6138-363D-11E5-9242-09173F13E4C5 n18:271B613B-363D-11E5-9242-09173F13E4C5 n18:271B6131-363D-11E5-9242-09173F13E4C5 n18:271B6132-363D-11E5-9242-09173F13E4C5 n18:271B612F-363D-11E5-9242-09173F13E4C5 n18:271B6130-363D-11E5-9242-09173F13E4C5 n18:271B6135-363D-11E5-9242-09173F13E4C5 n18:271B6136-363D-11E5-9242-09173F13E4C5 n18:271B6133-363D-11E5-9242-09173F13E4C5 n18:271B6134-363D-11E5-9242-09173F13E4C5 n18:271B612D-363D-11E5-9242-09173F13E4C5 n18:271B612E-363D-11E5-9242-09173F13E4C5 n18:271B612C-363D-11E5-9242-09173F13E4C5
n6:proteinBinding
Negligible
n6:synthesisReference
Purna Chandra Ray, Jagan Mohana Chary Tummanapalli, Seeta Ramanjaneyulu Gorantla, "Process for the Large Scale Production of Stavudine." U.S. Patent US20080312428, issued December 18, 2008.
n32:hasConcept
n33:M0027323
foaf:page
n5:zer1496.shtml n14:stavudin.htm n30:stavudine.html
n6:IUPAC-Name
n10:271B616E-363D-11E5-9242-09173F13E4C5
n6:InChI
n10:271B6174-363D-11E5-9242-09173F13E4C5
n6:Molecular-Formula
n10:271B6173-363D-11E5-9242-09173F13E4C5
n6:Molecular-Weight
n10:271B6170-363D-11E5-9242-09173F13E4C5
n6:Monoisotopic-Weight
n10:271B6171-363D-11E5-9242-09173F13E4C5
n6:SMILES
n10:271B6172-363D-11E5-9242-09173F13E4C5
n6:Water-Solubility
n10:271B6184-363D-11E5-9242-09173F13E4C5 n10:271B616C-363D-11E5-9242-09173F13E4C5
n6:logP
n10:271B6186-363D-11E5-9242-09173F13E4C5 n10:271B616A-363D-11E5-9242-09173F13E4C5 n10:271B616D-363D-11E5-9242-09173F13E4C5
n6:logS
n10:271B616B-363D-11E5-9242-09173F13E4C5
n7:hasATCCode
n8:J05AF04
n6:H-Bond-Acceptor-Count
n10:271B617A-363D-11E5-9242-09173F13E4C5
n6:H-Bond-Donor-Count
n10:271B617B-363D-11E5-9242-09173F13E4C5
n6:InChIKey
n10:271B6175-363D-11E5-9242-09173F13E4C5
n6:Polar-Surface-Area--PSA-
n10:271B6176-363D-11E5-9242-09173F13E4C5
n6:Polarizability
n10:271B6178-363D-11E5-9242-09173F13E4C5
n6:Refractivity
n10:271B6177-363D-11E5-9242-09173F13E4C5
n6:Rotatable-Bond-Count
n10:271B6179-363D-11E5-9242-09173F13E4C5
n6:absorption
Following oral administration, stavudine is rapidly absorbed (bioavailability is 68-104%).
n6:affectedOrganism
Human Immunodeficiency Virus
n6:casRegistryNumber
3056-17-5
n6:category
n6:clearance
* Renal cl=272 mL/min [Healthy subjects receiving 80 mg PO] * 594 +/- 164 mL/min [HIV-infected adult and pediatric patients following 1-hour IV infusion] * 9.75 +/- 3.76 mL/min/kg [HIV- Exposed or -Infected Pediatric Patients(Age 5 weeks – 15 years) following 1-hour IV infusion]
n6:containedIn
n13:271B615E-363D-11E5-9242-09173F13E4C5 n13:271B615C-363D-11E5-9242-09173F13E4C5 n13:271B615D-363D-11E5-9242-09173F13E4C5 n13:271B615A-363D-11E5-9242-09173F13E4C5 n13:271B615B-363D-11E5-9242-09173F13E4C5 n13:271B6158-363D-11E5-9242-09173F13E4C5 n13:271B6159-363D-11E5-9242-09173F13E4C5 n13:271B6156-363D-11E5-9242-09173F13E4C5 n13:271B6157-363D-11E5-9242-09173F13E4C5
n6:Bioavailability
n10:271B6180-363D-11E5-9242-09173F13E4C5
n6:Ghose-Filter
n10:271B6182-363D-11E5-9242-09173F13E4C5
n6:MDDR-Like-Rule
n10:271B6183-363D-11E5-9242-09173F13E4C5
n6:Melting-Point
n10:271B6185-363D-11E5-9242-09173F13E4C5
n6:Number-of-Rings
n10:271B617F-363D-11E5-9242-09173F13E4C5
n6:Physiological-Charge
n10:271B617E-363D-11E5-9242-09173F13E4C5
n6:Rule-of-Five
n10:271B6181-363D-11E5-9242-09173F13E4C5
n6:Traditional-IUPAC-Name
n10:271B616F-363D-11E5-9242-09173F13E4C5
n6:pKa--strongest-acidic-
n10:271B617C-363D-11E5-9242-09173F13E4C5
n6:pKa--strongest-basic-
n10:271B617D-363D-11E5-9242-09173F13E4C5